SiBone (NASDAQ:SIBN) Releases Earnings Results, Beats Estimates By $0.05 EPS

SiBone (NASDAQ:SIBN) issued its quarterly earnings results on Monday. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05, FiscalAI reports. The company had revenue of $55.70 million during the quarter, compared to analyst estimates of $55.31 million. SiBone had a negative return on equity of 7.62% and a negative net margin of 6.20%.

Here are the key takeaways from SiBone’s conference call:

• Third-quarter revenue rose 14.5% to $55.7 million, while U.S. procedure volume increased 19.5% and active physicians grew 16% to approximately 1,770. Management cited broad-based demand across surgeons, interventional spine physicians, and trauma procedures.
• The early alpha launch of iFuse Granite Onyx is generating demand ahead of the comparable Granite launch, including adoption by existing Granite users and new physicians. Onyx expands the company’s estimated addressable market to more than 650,000 procedures and approximately $5 billion.
• New spinal-fusion DRGs became effective October 1 and may increase hospital reimbursement by up to $50,000 for qualifying cases, supporting Granite adoption and potentially Onyx utilization. SI-BONE has also applied for an Onyx NTAP, which could take effect in October 2027 if approved.
• Profitability and cash generation improved, with adjusted EBITDA up 32.4% to $3.0 million, a 5.5% margin, and year-to-date operating cash flow of $4.4 million. The company lowered its expected 2026 operating-expense growth to 10.5% from 12% while reaffirming full-year revenue guidance of $231 million to $233 million.
• Average selling price declined because of a higher mix of lower-priced INTRA procedures in ASC and office settings and more two-implant Granite cases. Management expects modest gross-margin pressure in 2027 as it adds Onyx surgical capacity and launches additional products, although it continues to target long-term operating leverage.

SiBone Price Performance

SIBN traded up $1.43 during midday trading on Wednesday, reaching $25.20. 156,182 shares of the company’s stock were exchanged, compared to its average volume of 626,773. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -81.54 and a beta of 0.64. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. SiBone has a one year low of $11.48 and a one year high of $25.07. The business has a 50-day simple moving average of $19.50 and a two-hundred day simple moving average of $16.48.

Key SiBone News

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results topped forecasts. SI-BONE reported a Q3 loss of $0.08 per share, versus the $0.13 loss analysts expected, and revenue of $55.7 million versus $55.3 million expected. Revenue grew 14.5% year over year. Q3 results coverage
• Positive Sentiment: UBS raised its target and maintained a Buy rating. UBS increased its price target from $25 to $26, suggesting further upside from the cited $24.84 share price. UBS price target news
• Positive Sentiment: Operating trends and potential growth drivers were encouraging. U.S. procedure volume rose about 20%, and adjusted EBITDA and operating cash flow improved year over year. The company also highlighted new product clearance and reimbursement changes that could support adoption. SI-BONE Q3 results release
• Neutral Sentiment: 2026 revenue guidance was reaffirmed. SI-BONE expects revenue of $231 million–$233 million, broadly in line with the $232.2 million consensus estimate. The guidance offers stability but no clear upward surprise. SI-BONE guidance and results
• Neutral Sentiment: TD Cowen raised its target but left it below the current price. The firm lifted its target from $20 to $23 and kept a Buy rating. The higher target is a positive revision, though the $23 objective implies limited near-term upside at the cited $24.84 share price.
• Negative Sentiment: Two insiders sold shares. SVP Michael Pisetsky sold 29,665 shares and Anshul Maheshwari sold 3,738 shares. The sales may weigh modestly on sentiment, although both retained substantial holdings. Insider sale filing

Insider Buying and Selling

In other news, SVP Michael Pisetsky sold 29,665 shares of the stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $22.11, for a total value of $655,893.15. Following the completion of the transaction, the senior vice president directly owned 164,444 shares of the company’s stock, valued at approximately $3,635,856.84. This represents a 15.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jeffrey W. Dunn sold 20,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $18.47, for a total value of $369,400.00. Following the transaction, the director owned 16,057 shares of the company’s stock, valued at $296,572.79. This represents a 55.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 238,371 shares of company stock valued at $4,738,916. 4.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SIBN. UBS Group boosted their target price on shares of SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday. Needham & Company LLC reduced their price target on shares of SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a report on Tuesday. TD Cowen raised their price target on shares of SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup restated a “market outperform” rating on shares of SiBone in a research report on Tuesday. Finally, Truist Financial boosted their price objective on shares of SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.